Tg Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
TG Therapeutics' 2025 annual report reveals robust revenue growth driven by BRIUMVI, achieving substantial net income and advancing its key pipeline assets.
NASDAQ
TG Therapeutics' 2024 10-K filing highlights successful BRIUMVI commercialization, pipeline expansion, and a transition to profitability.
NASDAQ
TG Therapeutics is amending its annual report on Form 10-K for the fiscal year ended December 31, 2023, to address a material weakness identified in its internal control over financial reporting related to share-based payment awards.
NASDAQ
10-K: TG Therapeutics Reports Positive 2023 Results, Highlights BRIUMVI Launch and Pipeline Expansion
TG Therapeutics reports a profitable 2023 driven by BRIUMVI sales and a significant licensing deal, while also expanding its pipeline with a new CAR-T therapy program.